Section 646A.692 – Civil penalty.
(1) A manufacturer that fails to report or provide information as required by ORS 646A.689 may be subject to a civil penalty as provided in this section. (2) The Department of Consumer and Business Services shall adopt a schedule of penalties, not to exceed $10,000 per day of violation, based on the severity of each […]
Section 646A.693 – Prescription Drug Affordability Board; membership and qualifications of members; terms of office; duties; conflicts of interest; rules.
(1) The Prescription Drug Affordability Board is established in the Department of Consumer and Business Services to protect residents of this state, state and local governments, commercial health plans, health care providers, pharmacies licensed in this state and other stakeholders within the health care system in this state from the high costs of prescription drugs. […]
Section 646A.649 – Licensee’s principal place of business and registered agent; assumed business name; display of license; rules.
(1) A licensee shall designate and maintain a principal place of business at or from which the licensee engages in debt buying in this state and a registered agent in this state. (2)(a) If a licensee does not maintain a principal place of business in this state, the licensee shall nevertheless designate a registered agent […]
Section 646A.694 – Annual affordability determination for identified drugs and insulin products; criteria for and limitations on determination; confidentiality; rules.
(1) The Department of Consumer and Business Services shall provide to the Prescription Drug Affordability Board each calendar quarter a list of prescription drugs included in reports submitted to the department under ORS 646A.689 (2) and (6), a list of drugs included in reports submitted to the department under ORS 743.025 and a list of […]
Section 646A.652 – Required notices.
(1)(a) A licensee shall notify the Director of the Department of Consumer and Business Services in writing at least 30 days before the licensee relocates or closes the licensee’s principal place of business in this state. (b) In a notice under paragraph (a) of this subsection the licensee shall list the new address to which […]
Section 646A.695 – Annual fees assessed against drug manufacturers; rules.
(1) The Department of Consumer Business Services shall adopt by rule, in consultation with the Prescription Drug Affordability Board, annual fees to be paid by manufacturers that sell prescription drugs in this state. The fees shall be established in amounts necessary to meet the costs of the department and the board in administering ORS 646A.693 […]
Section 646A.655 – Compliance with director’s standards; rules.
A licensee or a person that engages in debt buying shall comply with standards that the Director of the Department of Consumer and Business Services adopts by rule. The standards, at a minimum, must require the licensee or the person to: (1) Establish appropriate training programs that instruct employees or agents of the licensee or […]
Section 646A.696 – Report to Health Care Cost Growth Target program and Legislative Assembly; contents of report.
No later than December 31 of each year, the Prescription Drug Affordability Board shall report to the Health Care Cost Growth Target program established in ORS 442.386 and to the interim committees of the Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information: (1) Price trends for the list […]
Section 646A.658 – Prohibited practices.
A licensee or a person that engages in debt buying may not: (1) Perform any act, undertake any practice or employ any device, scheme or artifice in the course of the licensee’s or the person’s business that the Director of the Department of Consumer and Business Services defines by rule as dishonest, unethical or illegal […]
Section 646A.697 – Study of market for generic drugs; effect of pricing on insurance premiums; report to Legislative Assembly.
(1) As used in this section, “generic drug” means: (a) A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j); (b) An authorized generic as defined by 42 C.F.R. 447.502; or (c) A drug that entered the market before 1962 that was not originally […]